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Abstract Background
There is evidence that hereditary neuropathies may coexist with inflammatory neuropathies, which are associated with pain and increased muscle weakness. It is debated whether immunomodulation is an effective treatment in these cases. We present data from a patient with genetically confirmed hereditary neuropathy with liability to pressure palsies (HNPP) and symptoms of a painful inflammatory neuropathy, which seemed responsive to intravenous immunoglobulin (IVIg).
Objectives
To assess the effects of IVIg on pain and muscle strength, and the need for continued treatment with IVIg, using an n-of-one randomised controlled trial.
Methods
We conducted a multiple crossover n-of-one trial in which IVIg and placebo infusions were administered in random order. Pain and self-reported muscle strength were assessed using a patient diary. We used Bayesian evaluation of informative hypotheses to compare the effect of IVIg and placebo on pain and muscle strength, and to assess the course of pain and muscle strength following IVIg infusions. Conventionally, a Bayes factor (BF) larger than 10 is considered strong support for a hypothesis.
Results
Four IVIg and three placebo infusions were administered. There was strong evidence that IVIg was superior to placebo in reducing pain to a clinically meaningful extent (BF=63.74). Similarly, there was strong evidence that IVIg was superior to placebo in increasing muscle strength to a clinically meaningful extent (BF=61.51). In addition, we showed that there was a continued need for IVIg infusions every three weeks to treat pain (BF=13.78) and muscle weakness (BF=15.67).
No adverse events occurred.
Conclusions
IVIg was beneficial in alleviating pain and muscle weakness in a patient with a genetically confirmed hereditary neuropathy (HNPP).
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BACKGROUND
Hereditary neuropathy with liability to pressure palsy (HNPP; tomaculous neuropathy) is an autosomal dominant disorder caused by a loss of function of the gene for peripheral myelin protein 22 (PMP22; OMIM #601097) on chromosome 17.p12. HNPP is a rare disorder, with an estimated prevalence of two to five per 100,000. [1] Symptoms usually start in the second or third decade of life and consist of recurrent painless episodes of focal sensory loss and muscle weakness (palsy) in the distribution of a peripheral nerve. Episodes are often provoked by compression of the nerve and resolve spontaneously within days to months. [2] [3] [4] There is no curative treatment; management consists of supportive measures to prevent nerve compression, and bracing to alleviate muscle weakness.
In this report, we describe the case of a female patient with HNPP who initally presented with symptoms of a painful neuropathy which were successfully treated with intravenous immunoglobulin (IVIg), as well as the results of a subsequent placebo-controlled n-of-one randomised controlled trial (RCT) that was conducted to formally assess the effects of IVIg on pain and muscle strength and the need for continued treatment with IVIg.
Case report
In 2002, a 35-year-old female patient presented to the Leiden University Medical Centre Neurology Clinic with a 15-month history of neuropathic pain in the right gluteal region that radiated via the back of the leg to the right foot. Four months before presentation, she had experienced weakness and sensory loss in the lower left leg after a prolonged car journey, but this resolved spontaneously after several weeks. Two months later, she experienced more severe weakness and sensory loss: she was unable to lift her left leg when lying prone and also experienced numbness in her left hand. No triggering events were reported for this episode.
Her medical history was unremarkable, and there were no family members with similar symptoms.
Her physical examination at the time of presentation showed mild proximal weakness of the left leg (MRC 4) and severe weakness (MRC 0-2) of the left foot extensor muscles.
Hypoalgesia was found in the ulnar side of the left hand and the left lower leg. She had reduced tendon reflexes; Achilles tendon reflexes were completely absent. The following examinations were normal or negative: lumbar MRI, cerebrospinal fluid analysis, serum anti-GM1, and serology for cytomegalovirus, Epstein-Barr virus, mycoplasma, and Borrelia burgdorferi. Faecal 4 tests for Salmonella, Shigella and Campylobacter were also negative. A nerve biopsy was not performed.
Electromyographic studies showed bilateral demyelinating conduction blocks at compression sites of the ulnar nerves, prolonged distal motor latencies of the right and leftsided ulnar, tibial, peroneal , and left median nerves, and absent F-waves in both peroneal and the right tibial nerves, consistent with HNPP, but also with definite electrodiagnostic criteria for chronic inflammatory demyelinating polyneuropathy (CIDP) according to the EFNS/PNS CIDP guidelines. [5] Based on these results, a preliminary diagnosis of CIDP was made and a DNA test for suspected HNPP was ordered.
She was treated with IVIg (0.4 mg/kg per day) for five days, which resulted in marked improvement: after three weeks she was able to do domestic chores again for the first time in a year. She continued to receive a maintenance dose of IVIg every three weeks, and her muscle strength continued to improve. The pain disappeared completely and she only suffered residual mild weakness of left foot dorsiflexion (MRC4). However, DNA analysis subsequently revealed a deletion of 17p11.2 including the PMP22 gene, and a definite diagnosis of HNPP was made.
Rationale for n-of-one trial
It remains debated whether genetic neuropathies can give rise to superimposed immunemediated neuropathies, [6] and the diagnosis of HNPP raised doubts whether continued IVIg was needed, especially given its high cost and limited availability. [7] In light of this ambiguity, the patient consented to a formal assessment of the effects of IVIg in an n-of-one trial. This is a multiple crossover trial in a single patient in which intervention and control treatment periods are randomised over time (e.g. AB-BA-BA). It is suitable to evaluate the effects of relatively fastacting, symptomatic treatment for chronic and relatively stable disease symptoms in individual patients. [8, 9] By means of the n-of-one trial, we aimed to evaluate the effects of IVIg on pain (primary outcome) and muscle strength (secondary outcome) in this patient with HNPP and an associated CIDP-like inflammatory neuropathy. The following hypotheses were tested: a) IVIg infusions reduce pain more than placebo infusions and this reduction is clinically meaningful; b) IVIg infusions increase subjective muscle strength more than placebo infusions and this increase is clinically meaningful. To assess the need for continued use of IVIg, we also tested the following 5 hypotheses: c) following IVIg, pain levels first decrease and then increase again; and finally, d) following IVIg, subjective muscle strength first increases and then decreases again.
METHODS
Trial design
We conducted a double-blind, multiple crossover n-of-one trial of four trial infusions that were given in hospital on an outpatient basis and in a randomised order at three week intervals. The intervention treatment consisted of intravenous immunoglobulin (0.4 mg/kg) and was compared to an inactive placebo infusion of 0.9% saline. A placebo infusion was chosen as comparator, because there is currently no pharmacotherapy for HNPP. The patient consented to participate in this study as a way to optimise her personal long-term clinical treatment.
A week after each trial infusion, an optional "rescue" infusion with the opposite treatment was offered (i.e. placebo if IVIg had been administered most recently and vice versa). The patient could accept or refuse this rescue infusion depending on her subjective assessment of the effects of the trial infusion (see Figure 1 ). The rescue infusion was offered to ensure that the most beneficial treatment was not withheld for more than a week after it was due according to her pre-trial 3-weekly treatment schedule. An open run-in period had shown that a 1-week delay in administering IVIg was not associated with unacceptable muscle weakness or pain. If the patient opted to have the rescue infusion, she returned to the randomisation schedule 3 weeks later.
Simple randomisation was carried out by the dispensing hospital pharmacy, which was also responsible for blinding of treatment by delivering all infusion packs to the hospital infusion room wrapped in opaque tin foil. This ensured that the patient and clinician remained blind to the order of the trial infusions, although both were aware that the rescue infusion was always the opposite one to the trial infusion given the week before. 
Outcomes and data collection
Pain was chosen as primary outcome measure and muscle strength as secondary outcome measure. Pain scores for the right leg, which had always been most affected by pain, were recorded by the patient three times per week in a patient diary at home. Pain was scored on a 14 cm visual analogue scale (VAS) ranging from 0 (indicating complete absence of pain) to 14 (worst possible pain imaginable). Ratings were converted into scores in millimetres, from which the percentage change from baseline was calculated. A clinically meaningful reduction in pain was defined as a 30% reduction compared to the baseline level of pain at the time of the last infusion. A reduction of this magnitude was previously found to correspond to 'some' to 'much' change in pain, and is associated with not needing rescue medication for chronic pain. [10] Analogous to pain, subjective muscle strength was recorded three times a week on a 14 cm VAS scale (0 = complete paralysis to 14 = normal strength for this patient). This was done for the left leg, which was most affected by weakness. Ratings were converted into scores in millimetres, from which the percentage change from baseline was calculated. No reference values were available from the literature and we chose to define a clinically meaningful 7 difference in muscle strength as an increase of at least 30% compared to baseline. Finally, at the time of each infusion, the patient was asked to report any side effects since the last infusion.
Data analysis
The effect of IVIg on pain and subjective muscle strength was assessed for the first 7 days after each infusion only (not longer because rescue infusions were offered 7 days after each randomised infusion). To assess the need for continued administration of IVIg every 3 weeks, the course of pain and subjective muscle strength was evaluated over the course of three weeks following IVIg. Coefficients were first estimated using SPSS version 20.0, followed by Bayesian evaluation of informative hypotheses using BIG. [11] Bayesian hypothesis testing allowed us to evaluate the inequality constrained hypotheses we had formulated regarding the magnitude of the increase/decrease following IVIg and placebo. [11] We compared the inequality constrained hypotheses that IVIg was superior to placebo to an unconstrained hypothesis which did not specify a relationship between the magnitude of the effect following IVIg and placebo infusions.
For each comparison, a Bayes factor was calculated, which is a measure of support for two competing hypotheses. A Bayes factor of 1 indicates that the data support both hypotheses equally. In the present study, a Bayes factor of more than 1 indicates that our (inequality constrained) hypotheses are more supported by the data than the unconstrained hypothesis, while a Bayes factor of less than one indicates the reverse. Conventionally, Bayes factors larger than 10 would denote strong support for the inequality constrained hypothesis. [12] A detailed description of the analyses is provided in Online Supplement 2, and the data archive is provided in Online Supplement 3.
RESULTS
The total number of infusions given during the trial was eight, but there were reasons to exclude data from one infusion for the analyses The reason for excluding data from one infusion is that the trial partly took place over the summer and the patient requested to receive one non-randomised and non-blinded IVIg infusion before her summer holiday. The results of this infusion were not used in the analyses; data for this infusion are not shown in tables or graphs. 
Pain
We first tested the expectation that the decrease in pain in the first 7 days after IVIg is greater than after placebo. We obtained a Bayes factor of 33.22 when we compared this hypothesis to the unconstrained hypothesis, providing strong evidence that IVIg reduces pain more than placebo. We obtained a Bayes factor of 13.40 when we compared the hypothesis that IVIg produces a clinically relevant reduction in pain (≥ 30%) to the unconstrained hypothesis, which implies that there is strong support for the hypothesis that IVIg reduces pain.
When these hypotheses were combined in a single hypothesis, i.e. pain decreases more rapidly after IVIg than after placebo in the first week after infusion, and it decreases to a clinically relevant level, and evaluated against the unconstrained hypothesis, we obtained a Bayes factor of 63.74. This strongly supported the hypothesis that IVIg has a clinically meaningful effect on pain, compared to placebo. Estimates and variances of the coefficients are shown in Table 1 . 
Subjective muscle strength
We assessed the effects on subjective muscle strength in a similar fashion. We obtained a Bayes factor of 36.24 when we compared the hypothesis that the subjective increase in muscle strength in the first 7 days after IVIg infusion would be greater than after placebo to the unconstrained hypothesis. This implies that there is strong evidence that IVIg increases muscle strength more than placebo. We then assessed whether the increase in subjective muscle strength could be considered meaningful, as expressed by a 30% increase in subjective muscle strength compared to the baseline muscle strength score for each infusion. We obtained a Bayes factor of 15.05 for the hypothesis that IVIg produces a clinically relevant increase in muscle strength (≥ 30%) when compared to the unconstrained hypothesis. This implies that there is strong evidence that IVIg increases muscle strength.
When these hypotheses were combined, i.e. muscle strength increases more rapidly and to a clinically relevant level in the first week after IVIg than after placebo, and evaluated against the unconstrained hypothesis, we obtained a Bayes factor of 61.51. This strongly supported the hypothesis that IVIg has a clinically meaningful effect on subjective muscle strength, compared to placebo.
Course of pain and muscle strength
Finally, to assess the need for regular IVIg infusions, we used quadratic models to test the hypotheses that pain first decreases and then increases again, and that muscle strength first increases and then decreases, in the three weeks following IVIg. The Bayes factor for the hypothesis about pain was 13.78, and the Bayes factor for the hypothesis about muscle strength was 15.67. These findings strongly support the notion that IVIg needs to be administered regularly to control pain and improve muscle strength. No adverse effects were reported during the trial.
Follow-up
We have now followed up this patient for 11 years. After the trial, she first continued to receive IVIg infusions every three to four weeks for two years, without any adverse effects. The interval was then successfully increased to five weeks. After a period of symptom stability, we attempted to give infusions every six weeks. However, this was followed by an increase in muscle weakness and pain, and the interval was reduced again to five weeks. Multiple EMGs during follow-up show signs of a long-term, progressive neuropathy rather than the regular episodic weakness seen in HNPP. An n-of-one trial to test the effect of treatment for this potentially coexisting inflammatory neuropathy, such as the one described for our patient, could be considered in these patients.
Clinical n-of-one trials, such as the one presented here, are a tool that can be used to guide appropriate treatment in rare diseases. [9] N-of-one trials have been used in the past to optimise treatment for individual patients, reduce unnecessary prescribing, and increase treatment compliance. [26, 27] Formal "trials of therapy", such as the one described in this study, can be valuable in guiding clinical practice when there is no evidence available from group-randomised clinical trials (RCTs), when the results of such trials do not necessarily generalise to one's patient in the consultation room, or when there are other pertinent reasons to optimise treatment, for example, because of the high cost of a medicinal product. [9] IVIg to treat inflammation associated with HNPP fulfils these criteria: there are no clinical treatment guidelines, there is no evidence from earlier trials available, and IVIg is costly to produce and its availability is limited. Moreover, many diseases for which IVIg is prescribed require long-term treatment [28, 29] , including when it is used to treat CIDP. The majority of patients require infusions every two to six weeks for a sustained response [7] , and a review suggests that it can be withdrawn in less than 15% without causing a relapse. [30] In our patient, increasing the interval between infusions from five to six weeks led to an unacceptable clinical deterioration.
N-of-one trials such as the current one may help to establish whether a particular patient has a true need for this type of treatment, and may thus aid appropriate prescription.
To our knowledge, this is the first randomised controlled trial (RCT) of IVIg to treat symptoms of inflammation in patients with HNPP; thus far, only anecdotal evidence suggested that IVIg may be effective in such patients. [4, 13, 14] The lack of RCTs may partly be due to the challenges associated with conducting RCTs in such small patient populations. [31] The n-of-one trial design could greatly facilitate the process of conducting RCTs in this type of patient population, since data from several n-of-one trials can be aggregated to obtain population effect estimates. [32, 33] Furthermore, Bayesian analysis methods, which can make use of prior knowledge, allow for continued updating of treatment effect estimates as new data become available.
[33] Thus, results from future trials in similar patients can be meaningfully combined with the results from the current trial to obtain an increasingly robust estimate of the population effect of IVIg to treat inflammation in patients with HNPP. Such personalised and adaptive approaches may also be useful in other situations where only very few patients are available for research. [31] Because this study was done in only one patient, its results may not necessarily generalise to other patients. Other limitations of the design include the need for multiple crossovers between the active and control intervention, which means that the participant burden in n-of-one trials is generally higher than in most other intervention research. Efforts should be made to reduce this burden and to prevent dropout during the trial. We chose to use a patient diary with two separate VAS scales to measure our outcomes and minimise the number of hospital visits for the patient. Although the VAS scale for pain has been extensively validated, [10] this was not the case with the VAS for subjective muscle strength. Furthermore, In conclusion, we presented a trial of a patient with HNPP and concomitant symptoms of pain and muscle weakness which improved after continued treatment with IVIg. This suggests that some patients with hereditary neuropathies may have co-existing inflammation, which is important to recognise because adequate treatment can improve their symptoms and quality of life. We also demonstrated the value of n-of-one trials for conducting research in rare conditions.
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